Medicine and Dentistry
Inflammatory Bowel Disease
71%
Ustekinumab
69%
Prospective Cohort Study
52%
Patient with Crohn's Disease
40%
Rheumatology
34%
Crohn's Disease
32%
Diseases
32%
Gout
29%
Myositis
23%
Infliximab
21%
Cross Sectional Study
19%
Ulcerative Colitis
19%
C Reactive Protein
17%
Pyoderma gangrenosum
17%
Arthritis
17%
Rheumatic Disease
17%
Proctitis
17%
Antiinflammatory Activity
17%
Shear Wave Elastography
17%
Echogenicity
17%
Tacrolimus
17%
Myopathy
17%
Disease Activity
17%
Salvage Therapy
17%
Doppler Ultrasound
17%
Spontaneous Remission
16%
Clinical Assessment
14%
Cytokine
14%
Patient-Reported Outcome
14%
Faecal Calprotectin
13%
Digitalis
13%
Placebo
12%
Disease-Modifying Antirheumatic Drug
11%
Microbiome
11%
Colchicine
10%
Biological Product
10%
Smoking
10%
Cohort Study
10%
Monoclonal Antibody
10%
Dermatosis
8%
Patient History of Surgery
8%
Colitis
8%
Stoma
8%
Disease Duration
6%
Gastroenterology
5%
Colorectal Surgery
5%
Diagnosis
5%
Rheumatoid Arthritis
5%
Enzyme Linked Immunosorbent Assay
5%
Bloody Diarrhea
5%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Ulcerative Colitis
54%
Prospective Cohort Study
52%
Ustekinumab
52%
Crohn's Disease
52%
Upadacitinib
52%
Tofacitinib
43%
Inflammatory Bowel Disease
41%
Cohort Study
24%
Antiinflammatory Activity
17%
Gout
17%
Krill
17%
Tacrolimus
17%
Proctitis
17%
C Reactive Protein
17%
Diseases
15%
Placebo
12%
Cytokine
11%
Colchicine
10%
Calgranulin
10%
Biological Product
9%
Patient History of Surgery
8%
Janus Kinase Inhibitor
8%
Adverse Event
7%
Monoclonal Antibody
7%
Clinical Trial
6%
Vedolizumab
6%